메이저 바카라 사이트

Samsung Bioepis (CEO: Kyung-Ah Kim) is expanding its footprint in the Korean biosimilar market through strategic partnerships with traditional South Korean pharmaceutical companies. Under this model, Samsung Bioepis develops and supplies biosimilars of global blockbuster drugs, while partners manage distribution and marketing based on their therapeutic strengths.

According to data confirmed by HIT News on July 2, Samsung Bioepis currently supplies five biosimilar products through partnerships with Korean firms. Boryung distributes the oncology biosimilars Samfenet (Herceptin) and Onbevzi (Avastin). Samil Pharmaceutical is responsible for the ophthalmology biosimilars Amelivu (Lucentis) and Afilivu (Eylea). Hanmi Pharmaceutical co-promotes the osteoporosis biosimilar Obodens (Prolia).

In parallel, Samsung Bioepis directly markets five other biosimilars: Adalloce (Humira), Etoloce (Enbrel), Remaloce (Remicade), Epyztek (Stelara), and Epysqli (Soliris).

The most recent addition to the Boryung partnership is Xbryk, a biosimilar for bone disorders. This marks their third collaboration following Samfenet and Onbevzi. Boryung’s sales strength is evident in the performance of Onbevzi, which posted approximately million in revenue last year, significantly contributing to Samsung Bioepis' oncology portfolio.

Joint promotion of Obodens with Hanmi Pharmaceutical also recently began. Approved in April, Obodens entered the market at 13% below the originator price. The two companies are actively targeting healthcare professionals through co-hosted symposia. Hanmi is positioning the product as an “evidence-based alternative,” drawing on its experience with the oral osteoporosis drug RaboneD.

These collaborations reflect Samsung Bioepis’ long-term strategy. Beginning with a licensing deal with Yuhan Corporation in 2017, the company has gradually built a network of alliances. Samfenet was originally partnered with Daewoong Pharmaceutical before transitioning to Boryung, while ophthalmic products were launched through Samil. The second ophthalmology collaboration with Samil, Afilivu, was signed last year, capitalizing on Samil’s specialized distribution channels.

The division of roles is clear: Samsung Bioepis focuses on R&D, manufacturing, and regulatory approvals, while local pharmaceutical companies handle commercialization. Though framed as licensing agreements, these collaborations effectively strengthen Samsung Bioepis’ sales infrastructure by leveraging the market expertise of its partners.

A company spokesperson stated, “Some pharmaceutical companies have well-established marketing and sales networks tailored to specific indications. By aligning with such firms, we are able to execute a strategy that maximizes profitability.”